ArticleCancer medicine2026
Real-World Data of Second-Line Amrubicin Monotherapy in Patients With Extensive-Stage Small Cell Lung Cancer Who Received First-Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemoimmunotherapy is widely used as the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), but treatment options for second-line have not changed. Amrubicin monotherapy is used as the standard treatment for relapsed SCLC, but since chemoimmunotherapy became an additional indication for ES-SCLC, the efficacy and safety of second-line amrubicin have not been sufficiently investigated.
methodsWe enrolled a total of 131 relapsed SCLC patients who received second-line amrubicin at eleven institutions in Japan between August 2019 and June 2023. We retrospectively examined the efficacy and safety of second-line amrubicin monotherapy.
resultsTwenty-five (19.1%) and 106 patients (80.9%) had sensitive and refractory relapse, respectively. 51 (38.9%) and 80 (61.1%) patients received first-line chemoimmunotherapy and first-line chemotherapy, respectively. The median progression-free survival (PFS) and overall survival (OS) were 3.6 months (95% confidence interval [CI], 3.1-4.1 months) and 7.9 months (95% CI, 6.7-9.1 months), respectively. The median PFS and OS were significantly longer in the sensitive group compared with the refractory group (PFS: 6.4 vs. 3.5 months, p = 0.008, OS: 9.4 vs. 6.4 months, p = 0.021, respectively). Treatment-related adverse events were as follows: Grade 4 neutropenia in 51 patients (38.9%), grade 3 or higher febrile neutropenia in 18 patients (13.7%), and all grade interstitial lung disease in 13 patients (9.9%). Treatment-related death was 1 patient (0.8%).
conclusionSecond-line amrubicin monotherapy for relapsed SCLC may be useful and well-tolerated as a treatment option after first-line chemoimmunotherapy or chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.